Search This Blog

Wednesday, May 8, 2019

Protagonist Therapeutics upgraded to Buy from Hold at Stifel

Stifel analyst Adam Walsh upgraded Protagonist Therapeutics to Buy from Hold and raised his price target for the shares to $17 from $11.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)